---
title: "Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293654319.md"
description: "Medpace Holdings (NASDAQ:MEDP) shares surged over 14% after reporting Q2 earnings of $4.25 and revenue of $707.33 million, both beating estimates. Driven by a 4.9% backlog growth to over $3.01 billion and strong new bookings, the company raised its fiscal 2026 EPS guidance to $17.25-$17.95 and revenue guidance to $2.805-$2.885 billion."
datetime: "2026-07-23T18:15:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293654319.md)
  - [en](https://longbridge.com/en/news/293654319.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293654319.md)
generator: "portal-rs"
---

# Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook

**Medpace Holdings Inc.** (NASDAQ:MEDP) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance.

The clinical contract research organization reported earnings of $4.25, beating the consensus of $3.97.

The company reported sales of $707.33 million, surpassing the consensus of $687.65 million.

Revenues increased 17.2% year over year, representing a backlog conversion rate of 24.1%.

EBITDA climbed 17.6% to $153.4 million, representing 21.7% of total revenue.

## Backlog Continues To Grow

Meanwhile, the company’s project backlog grew 4.9% year-over-year to over $3.01 billion. Net new business awards hit $795.7 million for the quarter, generating a healthy net book-to-bill ratio of 1.13x.

CEO **August Troendle** in the earnings conference call said, “Cancellations were well-behaved and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high-quality opportunities.”

“Overall, the environment remains constructive into July, and we are making good progress in positioning the business for 2027,” Troendle further commented.

## Medpace Raises Fiscal 2026 Guidance

Medpace on Wednesday raised its fiscal 2026 earnings from $16.68-$17.50 per share to $17.25-$17.95 per share compared to the consensus of $16.97.

The company also increased fiscal 2026 revenue guidance from $2.755 billion-$2.855 billion to $2.805 billion-$2.885 billion compared to the consensus of $2.778 billion.

EBITDA is expected to reach between $618.0 million and $642.0 million.

**MEDP Stock Price Activity**: Medpace Holdings shares were up 14.24% at $603.31 at the time of publication on Thursday, according to Benzinga Pro data.

 **Read Also: Jim Cramer: ‘Regional Banks Have Been A Fantastic Place To Be’** 

*Photo: Shutterstock*

### Related Stocks

- [MEDP.US](https://longbridge.com/en/quote/MEDP.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [Diversify Advisory Services LLC Invests $2.96 Million in Medpace Holdings, Inc. $MEDP](https://longbridge.com/en/news/296324211.md)
- [Medpace Holdings (MEDP) Rallies As Valuation Questions Grow](https://longbridge.com/en/news/296681298.md)
- [Medpace director Fred B. Davenport Jr disposes of 7,283 common shares for $4.41 million](https://longbridge.com/en/news/296649041.md)
- [Local Pensions Partnership Investment Ltd Buys 4,000 Shares of Medpace Holdings, Inc. $MEDP](https://longbridge.com/en/news/295998600.md)
- [If You Invested $100 In Medpace Holdings Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/295984118.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**